Drugs / TR-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07189195 | Nov 2025 → Nov 2029 expected | metastatic malignant neoplasm, pancreatic adenocarcinoma | University of California, Davis | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TR-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07189195 ↗ |
| Known as | BAQ13-LNP | “BAQ13-LNP (TR-002) as an autophagy inhibitor in patients with solid tumors (NCT07189195).” PMID 42247927 ↗ Jun 2026 |
| Route | Intravenous | “TR-002 administered intravenous weekly” NCT07189195 ↗ |